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RADIOFREQUENCY ABLATION VERSUS CRYOABLATION IN THE 




 Atrioventricular nodal reentrant tachycardia (AVNRT) is an abnormal heart 
rhythm caused by aberrant electrical conduction within the AV node. AVNRT is the most 
common type of paroxysmal supraventricular tachycardia (PSVT), with approximately 
50,000 new cases per year in the United States. Catheter ablation of AV node tissue has 
become the first-line definitive treatment for AVNRT, owing to its high efficacy, 
tolerability, and safety. Two modalities of ablation, radiofrequency (RF) and cryoablation 
are commonly utilized in clinical practice with high levels of success in treating AVNRT. 
To date, studies on the two modalities have compared metrics such as acute success rate, 
procedure time, fluoroscopy time, and recurrence of AVNRT. Recurrence of AVNRT has 
been observed as far as 10 years after RF ablation. In patients with a history of RF 
ablation for AVNRT, rates of atrial fibrillation are higher than that of the general 
population. However, long-term studies directly comparing RF and cryoablation 
outcomes do not exist. This retrospective cohort study is designed to examine the rates of 
AVNRT recurrence and new arrythmias in patients 10 to 15 years after receiving either 
RF or cryoablation. To accomplish this, eligible participants will have their medical 
records reviewed for documentation of AVNRT recurrence, atrial fibrillation, atrial 
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flutter, and complete AV block requiring pacemaker implantation. In doing so, we hope 
to give providers more insight into the risk profiles for each modality.  
 
 vi 
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Atrioventricular nodal reentrant tachycardia (AVNRT) is an abnormal heart 
rhythm caused by aberrant electrical conduction within the AV node and surrounding 
tissue. Episodes can last from seconds to hours. They may self-resolve or require 
intervention to return to sinus rhythm. Though AVNRT is generally not life-threatening, 
it can cause debilitating symptoms that impact quality of life. These include 
lightheadedness, palpitations, chest discomfort, and presyncope. In rare cases, AVNRT 
may result in sudden cardiac arrest and death.1 
 AVNRT is the most common type of paroxysmal supraventricular tachycardia 
(PSVT). Of the estimated 570,000 living with PSVT in the United States and 89,000 new 
cases per year, 56-60% are AVNRT.2–4 Approximately two thirds of patients with 
AVNRT are women.4,5 While age at first onset of symptoms is more common in a 
patient’s teens or twenties, others may present with AVNRT later in life, even into the 
seventh or eighth decade.3,5 
Severity of the accompanying symptoms of AVNRT can vary widely between 
patients. Asymptomatic AVNRT can go undetected and may not require intervention. For 
symptomatic episodes, physical maneuvers such as Valsalva and carotid massage are 
moderately effective in breaking the aberrant rhythm.6,7  If unsuccessful, first-line 
treatment is intravenous adenosine or synchronized electrical cardioversion, which are 
highly effective at returning a patient to sinus rhythm.8–10  
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Catheter ablation has emerged as first line therapy for definitive treatment to 
prevent recurrent AVNRT. Catheter ablation is better tolerated and more effective than 
chronic pharmacological treatment with beta-blockers.11 Two modalities, radiofrequency 
ablation (RF) and cryoablation have proven to be effective options for permanent 
definitive treatment of AVNRT. Some risks, however, exist with ablative procedures. 
Perhaps the most well-documented is complete AV block, requiring pacemaker 
implantation. While high grade AV block was seen quite commonly at the advent of RF 
ablation (in as many as 1 in 5 patients), the absolute risk of AV block has decreased 
markedly as improved techniques and knowledge of the procedure have developed.12,13 
Limited data exist documenting the long-term outcomes of catheter ablation. Among the 
few long-term studies following AVNRT patients post-ablation, rates of other 
supraventricular arrythmias, such as atrial fibrillation (AF), have been noted to be higher 
than in the general population.14,15 Ablated myocardial tissue viewed under microscope 
reveals markedly different histological findings depending on the ablation modality 
used.16,17   Theoretically, atrial remodeling around ablation lesions could produce a 
proarrhythmic environment over time, making ablation lesions potential substrates for 
future arrythmias. 
 
Statement of the Problem 
Ablation has become a first-line definitive treatment of AVNRT, owing to its low 
procedural risks and high efficacy. Two different modalities of ablation have emerged, 
each showing high levels of effectiveness in treating AVNRT and low perioperative 
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morbidity. However, long-term data following outcomes of patients undergoing RF 
ablation and cryoablation is scarce. Several groups have explored recurrence rates of 
AVNRT over a short follow-up period after either RF or cryoablation.18–21 Others have 
retrospectively studied the long-term outcomes of RF ablation patients extending more 
than 10 years post-procedure.14,15 But there still remains a scarcity of data directly 
comparing long-term recurrence rates in patients receiving the two modalities of ablation. 
Similarly, observed rates of newly-developed AF is higher in patients who have received 
RF ablation for AVNRT,14 but no similar extended study of cryoablation patients exists 
to date. We hope to elucidate the long-term relative successes and risks of the two 
methods, so that practitioners and patients can make an informed decision when selecting 
an ablation modality for their patients.  
 
Hypothesis 
Patients that have undergone cryoablation will have higher incidence of AVNRT 
recurrence than those who underwent RF ablation after extended follow-up. 
 
Objectives and Specific Aims 
Our objective is to elucidate the difference in long-term arrythmia risks of the two 
modalities of cardiac catheter ablation to treat AVNRT. We will measure the difference 
in recurrence of AVNRT among patients treated with cryoablation and those treated with 
RF ablation in a period of 10-15 years post-procedure. Similarly, we will measure the 
rates of de novo arrythmias between these groups over the same time span. Lastly, we 
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will evaluate patients’ self-reported quality of life change since ablation, to gain a deeper 
understanding of how the net benefit of these procedures outweigh the potential risks. 
Specifically, we will: 
1) Measure incidence of AVNRT recurrence over a period of 10-15 years post-
ablation procedure in patients receiving RF ablation and cryoablation.  
2) Measure incidence of newly-acquired atrial fibrillation, atrial flutter, and AV 
nodal block requiring pacemaker implantation over a period of 10-15 years post-
ablation procedure in patients receiving RF ablation and cryoablation. 
3) Compare patient perceived quality of life change since ablation procedure 




REVIEW OF THE LITERATURE 
Overview 
Pathophysiology:  
The atrioventricular (AV) node is a 5x3x1mm structure located at the apex of the 
triangle of Koch, a region defined by three boundaries, the coronary sinus orifice, tendon 
of Todaro, and septal leaflet of the tricuspid valve. As a key component in the specialized 
conduction system of the heart, the AV node is responsible for electrically connecting the 
atria and ventricles of the heart. It can do so via two pathways, a "fast" pathway (FP) and 
"slow" pathway (SP), which bifurcate then rejoin at a shared lower common pathway 
(LCP). As their names suggest, the fast pathway transmits quickly but has a longer 
refractory period, while the slow pathway transmits slowly but with a quicker refractory 
period (Figure 1). During transmission of a typical sinus impulse, conduction travels 
down both pathways in parallel. The impulse traveling down the FP will reach the LCP 
first and proceed down the bundle of His, leading to normal ventricular depolarization. 
The impulse from the SP, lagging behind, reaches the lower common pathway second, 
reconnecting with the FP in the latter’s refractory period and causing the impulse from 
the SP to be terminated. However, a critically timed premature atrial contraction (PAC) 
can cause conduction in the SP while the FP is still refractory. When this impulse reaches 
the LCP, provided the fast pathway terminus has recovered and is now excitable, it can 
cause retrograde conduction back up the FP. This can result in a “short-circuit” of 
repetitive conduction down the SP and back up the FP, leading to a sustained and regular 
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tachycardia. This is the underlying mechanism of “slow-fast AVNRT” or “typical 
AVNRT.” Typical AVNRT makes up 80-90% of all AVNRT cases.22,23  
 
Figure 1: Dual AV nodal physiology (Adapted from McGuire et al. 1993)24 
This is a visual depiction of dual AV nodal physiology described above. (UCP: Upper 
common pathway, SP: Slow pathway, FP: Fast pathway, LCP: Lower common pathway) 
Left (A): A normal impulse bifurcates into SP and FP, with FP propagating on and SP 
terminating upon reaching a refractory LCP. Right (B): An impulse traveling down SP 
and then retrograde up FP starts the re-entry circuit characteristic of slow-fast AVNRT. 
 
History:  
The dual AV nodal physiology was first demonstrated to be present in dogs by 
Moe in 1956.25  It was later demonstrated in human patients with AVNRT by Denes in 
1973.26 Surgical dissection of the AV node as curative treatment for AVNRT was first 
described by Ross in 1985.27 By the late 1980’s several groups were testing application of 
high energy to the AV node via catheter ablation, noting successful treatment of PSVT 
but high-grade AV block in as many as 21% of patients.12,28,29 In 1992, Jackman and 
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Jazayeri described the effectiveness of RF catheter ablation of either the slow pathway or 
fast pathway with slow pathway ablation having a superior risk profile relating to AV 
block.29,30 In the early 2000’s, cryoablation emerged as an alternative to RF that seemed 
to show an even lower risk of AV block.20,31,32 Use of both cryoablation and 
radiofrequency ablation is widespread as definitive treatment, and the two are typically 
regarded as equally viable options. 
 
Clinical presentation: 
The most common symptoms that accompany AVNRT are palpitations, 
presyncope, shortness of breath, lightheadedness, diaphoresis, and chest pain. 
Alternatively, AVNRT episodes can be asymptomatic. In rare cases, AVNRT can result 
in syncope. This is most often seen with patients whose tachycardia reaches higher heart 
rates, above 170, where insufficient time for ventricle filling leads to decreased cardiac 
output and decreased perfusion of brain tissue.3 Rarer still are cases of AVNRT linked 
with cardiac arrest and death.1 
 
Epidemiology/Demographics:  
An estimated 570,000 people in the United States have some form of PSVT with 
approximately 89,000 new cases per year.2 Between 56-60% are AVNRT.3,4 Other cases 
may go unreported for a number of reasons. Because symptomatology varies greatly, 
some patients may not feel their symptom severity warrants medical attention. Others 
may not be aware of the rhythm when they experience it. 
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AVNRT is more common in women, who make up 63-68% of the patient 
population.4,5 The underlying reason behind the gender discrepancy is unclear, though 
proposed mechanisms include the slowing effect of estrogen on AV nodal conduction 
observed in animal models.33 Among AVNRT patients, female patients have a shorter 
average SP refractory period, which would widen the window for timing of a PAC to 
potentially trigger a re-entry cycle.5 
Age at first onset of AVNRT symptoms is significantly younger in those with no 
associated heart disease and older in those with associated heart disease.2,5 This bimodal 
distribution suggests a difference in underlying mechanism or arrhythmogenesis and 
underscores a need for further research.  
 
Prevention and Treatment 
Antiarrhythmic drugs including bisoprolol and diltiazem were historically used 
for prophylaxis against AVNRT in patients with regular episodes, but these drugs are not 
as effective or well-tolerated when compared to ablation.11 Several antiarrhythmic 
medications used in chronic treatment of AVNRT carry potential proarrhythmic side 
effects as well.34 When factoring the costs of medication and office or hospital visits for 
breakthrough episodes, an ablation procedure reduces long-term costs for patients when 
compared with chronic pharmacological treatment.11,35,36 Ablation appears even more 
favorable when considering a large portion of the population suffering from AVNRT are 
below the age of 30, making life-long drug therapy unattractive when compared against a 
one-time permanent intervention.2 
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Unsurprisingly, then, the definitive choice for AVNRT treatment has become 
ablation. SP ablation has become favored over FP ablation owing to higher acute success 
rates and lower rates of complete AV block.29,30 Within the category of ablation exist two 
effective and evidence-supported modalities, radiofrequency (RF) ablation and 
cryoablation. 
RF ablation works by applying a catheter tip to deliver conductive heating above 
50C to target myocardial tissue, causing irreversible damage and destroying the tissue’s 
electrical conduction capabilities. On tissue pathology, destruction of lipid membranes 
and structural proteins is seen, and cell architecture is greatly disturbed. At the center of 
the lesion is a zone of coagulation necrosis. Surrounding the central zone of the lesion, 
where application of heat is not direct, changes in cell architecture are appreciated but 
some myocytes can survive and retain function.37 
Cryoablation works by delivering liquid nitrogen to the catheter tip, causing ice 
crystal formation of surrounding tissue. The freezing and thawing of the ice results in 
increased membrane permeability and functional impairment of mitochondria in affected 
cells. The inflammatory and scarring process in the following weeks ultimately leave a 
well-defined collagenous and fatty lesion.16 
 
Technical Considerations of Cryoablation versus RF 
Certain technical features of the cryoablation modality support its case as a safer 
alternative to RF. One is the documented concept of cryomapping.16,17,19,21 When 
determining whether a tissue area of interest is the desired site of cryoablation, the 
operator can give a test application with the catheter tip to “cryomap” the area before 
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committing to applying a therapeutic temperature. This involves applying a 
subtherapeutic temperature (-30C) for a short period of time (~60s) and observing. This 
lesion is temporary and its effects reversable but gives the operator insight into how 
effective and safe the location will be to ablate. If AVNRT is still inducible after the test 
freeze, the locus may not be an effective ablation target. If the test freeze results in full 
AV block, this indicates the area is not safe for ablation. The AV block will resolve 
shortly thereafter and an alternative tissue target can be chosen. No such reversable test 
application is possible during RF ablation due to the nature of how RF energy damages 
cells. 
The next built-in safety feature of cryoablation is that of “cryoadhesion”. During 
the freezing process, myocardial tissue adheres to the catheter tip. This prevents the 
desired ablation target from breaking contact with the catheter mid-ablation and, in doing 
so, avoids accidental ablation of unwanted areas. In contrast, RF catheter placement, 
without the benefit of adhesion, is more susceptible to instability from patient movement 
from pain, respiration, and the rapid movement of heart tissue during tachycardia.16,18 
This is exacerbated by the fact that RF ablation involves a higher level of patient reported 
pain than cryoablation.13 This creates a greater potential for ablation of unintended tissue 
and likely contributes to the differences seen in the morphology between the often 
irregular RF lesions and the typically well-defined cryo lesions. Because of patient 
movement and the inherent catheter instability, RF catheter tip often makes contact with 
tissue around the central target. This causes RF lesions to often cover a larger surface 
area and be described as “brush lesions.” Cryoablation lesions, owing to cryoadhesion, 
 
11 
are often described as “focal lesions.”16,17 Lesions created during cryoablation are more 
homogenous than those made during RF ablation, which may cause them to be less 
proarrythmatic.15,16 
Cryoadhesion also allows cryoablation to reduce its total fluoroscopy time. 
Fluoroscopy is used to ensure stable and precise catheter position which is critical to 
ensure the correct tissue is being ablated. For RF, this requires continuous fluoroscopic 
monitoring over the course of the ablation, exposing patient and operating team to longer 
potential periods of radiation. Cryoadhesion ensures the catheter tip and target 
myocardial tissue are adhered during ablation without this continuous direct monitoring, 
allowing fluoroscopy to be intermittently turned off, reducing radiation exposure to the 
patient and team. 
There is some debate about the respective advantages and disadvantages of 
catheter tip size in cryoablation. While a 4-mm catheter tip is the standard for RF 
ablation, two sizes of catheter tips, 4-mm and 6-mm, are both commonly used for 
cryoablation. Some studies have suggested improved efficacy and reduced recurrence 
with the use of 6mm catheter when compared with 4mm catheters.18,20 However a meta-
analysis by Hanninen et al. found no difference in acute success or long-term recurrence 
of AVNRT between 4-mm or 6-mm catheters.13–15 
Cryoablation has increased in popularity for the treatment of pediatric AVNRT, 
where avoiding a permanent AV block may take higher priority, given the possibility of 
longer remaining life with this added morbidity. Cryoadhesion allows cryoablation to 
leaves smaller, more regular lesions. In addition cryoablation causes less damage to cell 
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architecture, which makes it more attractive in the still-growing pediatric heart.16 
However, cryoablation uses a more bulky catheter, which may be more difficult to 
navigate through the smaller anatomical structures of children.16 For these reasons, a 
4mm catheter tip may be theoretically favorable to a 6mm tip when performing 
cryoablation in the pediatric population. 
 
Justification of Research 
With catheter ablation emerging as the clearly favored treatment for AVNRT, we 
seek to gather more information on the relative strengths and weaknesses of different 
ablation modalities, namely radiofrequency and cryoablation. While there has been some 
research assessing relative acute success rates, scarce information exists about the long-
term outcomes of such procedures, mostly limited to recurrence. Even scarcer 
information is available about newly developed arrythmias after ablation, despite 
evidence suggesting the proarrhythmic nature of similar lesions. Investigation into the 
long-term outcomes of cryoablation and RF ablation has the potential to guide clinical 
decision making when weighing the two options. 
Prior studies have compared them on the basis of perioperative metrics such as 
procedure length, fluoroscopy length, number of energy applications given, total ablation 
time, incidence of temporary AV block, and acute success rate, best defined as absence of 
inducible AVNRT with electrical stimulation. Long-term metrics have included 
recurrence of AVNRT and permanent AV block. In select studies, long-term metrics have 
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been extended to include development of de novo arrythmias.14,15 However, study of 
newly developed arrythmias has been limited to subjects receiving RF ablation. 
 
Existing Research 
Schwagten et al. (2011) 
 A Dutch retrospective study of 274 patients sought to compare outcomes of 
cryoablation and RF ablation for AVNRT and evaluate patients’ perceived quality of life 
since the procedure.18 The study included consecutive patients undergoing either 
procedure from 1999-2007. Acute success rate differences were not statistically 
significant (RF 96.2% (126/131), cryo 96.5% (138/143) p=0.89). Number of catheter 
applications was higher in the RF group (Cryo 2 ± 22, RF 9 ± 86, p<0.001), as was 
fluoroscopy length (RF 27 ± 22 min, cryo 19 ± 15 min, p<.002). Total ablation time was 
higher in the cryo group (Cryo 522 ± 384, RF 317 ± 621, p<.001), but there was no 
statistically significant difference found in total procedure length (RF 138 ± 71 min, cryo 
146 ± 60 min). Similar rates of temporary AV block were found (Cryo 4.2%, RF 5.3%, 
p=.67). After a mean follow-up of 4.3 ± 2.5 years, long-term procedural success was 
reevaluated. Frequency of redo procedures over the follow-up period was used as a proxy 
for long-term procedural failure rate. Differences in redo procedure rate were not 
statistically significant (cryo 11%, RF 5%, p=.11). Of note, 2 patients within the RF arm 
had permanent AV block after the procedure, requiring pacemaker implantation. The 
research group concluded that both modalities are safe and effective.  
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The study also incorporated a questionnaire in which patients were asked about 
recurrence of arrythmia-related symptoms, emergence of other symptoms, and a question 
on their perceived quality of life change since the procedure (Figure 2). The perceived 
quality of life change was similar among the two arms. In the cryo group, 89% reported 
quality of life had improved since the procedure, whereas 88% in the RF group reported 
improvement. 
 
Figure 2: Quality of life change after ablation for AVNRT (adapted from Schwagten 
et al. 2011)18 
Above displays the responses of participants when asked if they felt improvement, no 
difference, or deterioration in their quality of life after the cryoablation (cryo) or 
radiofrequency (RF) ablation. 
 
Notably, the patient population of the study was older than typical AVNRT 
population. The mean age was 51 ± 17 years (Cryo 50 ± 17, RF 52 ± 17 years). This 
raises concern about the generalizability of the study’s findings as it relates to AVNRT 
patients as a whole population. 
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It was never explicitly stated whether any other patients aside from those who 
received repeat procedures had recurrence of AVNRT, which leaves the possibility that 
the long-term failure rate presented may underestimate the true rate. 
The questionnaire was given at different stages post-procedure; for some as soon 
as one-year post ablation, while for others it was as many as 9 years. For those 
completing the questionnaire on the shorter side of this window this may not represent a 
long enough observation period to adequately assess recurrence. 
Of the 61% of subjects who responded to the questionnaire, 48% (cryo 48%, RF 
48%) reported “late arrythmia symptoms” though these are of uncertain clinical 
significance.  
 
Rodriguez-Entem et al. (2012) 
A prospective, randomized study of 119 patients (60 cryoablation, 59 RF) in 
Spain compared cryoablation with radiofrequency ablation for AVNRT using similar 
metrics over a shorter term.20 Between 2008 and 2010, patients received either 
cryoablation or RF ablation and were followed-up for an average of 252 days post-
procedure. The two groups showed similar rates of acute success (RF 100%, cryo 98%) 
and procedure length. Fluoroscopy duration and application number were significantly 
higher in the RF group. Recurrence of AVNRT before or at follow-up was significantly 
higher in the cryoablation group (cryo 15%, RF 3.4%, p<0.03; Figure 3). One patient in 
the RF group required pacemaker implantation for complete AV block. Notably, the 
study used 6mm catheter tips for cryoablation. They suggested, as the Dutch study above 
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also posited, that 6mm and longer application times improves the acute success rate of 
cryoablation. This idea however, is at odds with a meta-analysis finding no difference in 
acute success nor recurrence rates between 4-mm and 6-mm catheter tips for 
cryoablation.13  
 
Figure 3: AVNRT Recurrence over time following ablation (adapted from 
Rodriguez-Entem et al. 2012)20 
Above displays the study’s findings regarding recurrence of AVNRT in the 252 days 
following ablation. X-axis: Time in days post-procedure, Y-axis: percentage of 
participants who remained arrythmia-free  
 
Randomization ensured no selection bias went into which patients received which 
ablation modality. However, this study had its own limitations. The study included 
patients with other preexisting structural heart disease (3 in the cryo group, and 4 in the 
RF group) which could contribute to arrhythmogenesis independent of ablation. The 
average time to follow-up was again a limitation. Ultimately, our interests in 
investigating long-term outcomes require a longer observation period than the 252-day 
average follow-up used in this study. 
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Kimman et al. (2004) 
Another Dutch group conducted a prospective randomized study to compare 
outcomes in 63 patients (33 RF, 30 Cryo) receiving slow pathway RF and cryoablation 
for AVNRT.21 After a mean follow-up period of 13 months, acute success (Cryo 91%, 
RF 93%), procedural length (Cryo 142.5, RF 144), fluoroscopy duration(Cryo 29.2, RF 
35.2) and recurrence rates (Cryo 10.0%, RF 9.1%) were not significantly different 
between groups. Randomized prospective trials like this one offer the benefit of avoiding 
selection bias in which patients are placed into each treatment arm. But this study was 
arguably underpowered. Due in part to small sample size, the study was only able to 
show significant difference in application number (Cryo 2, RF 7, p < 0.005). It is also 
unclear how the study screened for AVNRT recurrence. The paper’s methods state 
patients were given a home EKG to record while experiencing symptoms for 3 months 
post-procedure but presents the incidence of recurrent AVNRT for a period of 12 months 
after the ablation. There is no mention of electrophysiology study or other test or tool 
used at follow-up, making it unclear how the incidents were detected after the initial 3 
months of observation. 
 
Kimman et al. (2005) 
The same group retrospectively studied 120 patients who received one of three 
different forms of RF ablation between 1991 and 1995 with a mean 10.1 year follow-
up.15 Patients either received slow pathway ablation (n=47), fast pathway ablation (n=40) 
or “slow and fast” pathway ablation (n=33). 
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The study found no AVNRT recurrences after 3 years post-procedure. Perhaps 
most alarmingly, they found that 24% of patients had new arrythmias or late AV block. 
This figure, comparatively higher than other studies, may overestimate ablative therapy’s 
real risk. This may in part be due to the definition of “new arrythmia” being extended to 
premature atrial contractions (PACs). In fact, PACs made up the majority of this category 
(16/29). Given that precisely timed PACs are often the initiator of AVNRT rhythm, it is 
highly likely that many of patients experienced PACs before ablation and were merely 
masked by the sustained tachycardia that they precipitated. As discussed earlier, RF 
lesions can contribute to arrhythmogenesis but it appears dubious to claim a causal 
relationship between the ablative procedures and the 16 “new” instances of PACs seen in 
the study. The clinical significance of the PACs is also debatable when compared with 
other arrythmias that carry much greater potential morbidity, such as the risk of 
thromboembolism with AF. Thus, PACs may warrant separate categorization. Other new 
arrythmias found were 9 cases of atrial fibrillation, 6 cases of atrial tachycardia, and 1 
case of atrial flutter.  
Of note, the study included patients with preexisting structural heart 
abnormalities. Two of the patients who developed atrial fibrillation post procedure were 
found to have structural heart abnormalities, one with mitral valve disease and one with 
enlarged atria. Such structural problems can themselves be a source of arrhythmogenesis, 
casting doubt on whether the ablation procedure played a role in their AF development. 
The study also included patients with other pre-existing arrythmias on top of 
AVNRT: 4 with atrial flutter, 1 with atrial tachycardia (unspecified type), and 1 with 
 
19 
atrial fibrillation.  None of these patients were noted to have these arrythmias after 
successful AVNRT ablation or at follow-up. 
It should be noted that slow pathway ablation, which has become standard 
practice, was only used in 39.2% of patients. The fast pathway group and “fast and slow” 
pathway group both had higher incidence of AV block when compared with the slow 
pathway group (fast 33%, fast and slow 21%, slow 11%). The use of fast and “fast and 
slow” ablation explains in part the higher arrythmia rates when compared with similar 
research. Lower risk of AV block with slow pathway ablation has been demonstrated 
elsewhere, and slow pathway ablation is now favored because of its increased safety.29 
In their discussion, the group suggests that receiving a higher level of RF energy, 
and not greater application number, creates higher risk for future arrythmia. This is an 
area of potential future research. 
This study was notable insofar as it was the first to explore extended follow-up of 
AVNRT ablation patients and new arrythmias but questions remain about its relevance to 
current practice. In light of recent literature supporting slow pathway for its greater 
efficacy and safety, the results of this study, which used fast pathway and “fast and slow” 
pathway ablation in two of its treatment groups, should be taken in context. 
 
Frey et al. (2019) 
A more recent Austrian study sought to explore the relationship between RF 
ablation for AVNRT and development of other arrythmias long-term.14 This retrospective 
study included 534 consecutive patients who received RF slow pathway ablation between 
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1994 to 1999 with an average 15.5 year follow-up period. The group found that 2.7% of 
patients had recurrence of AVNRT and 11.9% had new-onset atrial fibrillation at follow-
up. Recurrence occurred as soon as 11 months to as far as 10 years post-ablation. This 
supports the argument for longer observation periods, in contrast with Kimman et al. who 
saw no new recurrences after 3 years post-procedure.15 
New onset AF was predicted by arterial hypertension (OR 2.61, 95% CI 1.14–
5.97,p < 0.03), age (OR 1.05, 95% CI 1.02–1.09, p < 0.005) and prolonged atrial-His 
interval during postintervention electrophysiology (EP) study (OR 1.02, 95% CI 1.01–
1.04, p < 0.05). 
The incidence of new AF in the study population was surprisingly high when 
compared with larger population studies on AF prevalence. The Rotterdam study, a 
massive population-based prospective cohort study in Europe found overall prevalence in 
the general population was 5.5%.38 The CDC estimates that, among the United States 
population, 2% of people under age 65 and 9% of people above the age of 65 have AF.39 
The prevalence within the study group is well above these marks for both age groups. 
Differences in AF rates between the general population and subjects following RF 
ablation were more noticeable in younger age groups (Figure 4). There are several 
explanations, some of which we have discussed above. Damage caused by RF energy 
permanently damages underlying cell architecture and creates heterogenous lesions that 
can be substrates for future arrythmias. Alternatively, AVNRT and AF might share 
similar risk factors. There could also possibly be a genetic component that may contribute 
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to predisposition towards developing both AVNRT and AF, though nothing of this nature 
has been identified at this time. 
 
Figure 4: Incidence of new-onset AF after RF ablation for AVNRT (adapted from 
Frey et al. 2012)14  
Above is a depiction of the data collected by Frey et al. regarding incidence of new-onset 
AF in subjects who received RF ablation, compared with general population data from 
the Rotterdam Registry, stratified by age group. 
 
Actual AF prevalence within the study population could be higher than the 11.9% 
presented. This is because researchers only confirmed cases already diagnosed by 
patients’ general practitioners and did not systematically screen or test for AF at follow-
up. Cases of asymptomatic AF or cases in patients with lapses in regular care may not 
have been detected. 
The questionnaire and records-based nature of the study highlights some of the 
study’s other limitations. Data was only collected from 61.6% of subjects. A significant 
portion of the original study population was lost to follow-up or died unrelated to 
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procedure, a drawback of the lengthy observation period. The study relied upon a 
substantial amount of self-reported information, allowing for potential issues of recall 
bias. Lastly, as with the other 10+ year study by Kimman et al., the study did not collect 
data on cryoablation for comparison but does support the idea that RF lesions have long-
term proarrhythmic consequences.  
 
Summary of Existing Literature 
To summarize the existing research, both RF and cryoablation are accepted as 
highly effective and safe treatments for AVNRT. Acute procedural success slightly 
favors RF ablation in some studies, while others find similar efficacy among the two 
groups. RF carries risk of permanent complete AV block, necessitating implantation of a 
pacemaker, while cryoablation carries little to no risk of permanent AV block. RF 
necessarily requires more fluoroscopy time and more catheter applications. However, 
procedural time between modalities is comparable. Patients report improved quality of 
life after undergoing ablation regardless of modality.  
With all factors considered, neither modality can claim superiority in the general 
population but in select populations, one may be preferable and more widely used. For 
instance, within the pediatric population, an increased risk of complete AV block that 
comes with RF may outweigh an increased risk of recurrence with cryoablation. Choice 
of modality will often come down to the operator’s preference and clinical judgement. 
There is more to be learned about each modality’s proclivity towards recurrence 
of AVNRT. Data regarding recurrence rates vary, with some studies heavily favoring RF 
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and others finding no significant difference. However most existing studies to date are 
limited to short-term outcomes and those with longer follow-up are limited to RF 
patients. With cryoablation’s growth in usage since the early 2000’s, there exists new 
data which will allow an analysis of the two modalities side by side.  
The findings of Frey et al. highlight a gap in knowledge that still exists regarding 
long-term risks of development of new arrythmias. New-onset AF rates in patients who 
received RF ablation was much higher than expected when compared to the general 
population. This is presently an unexplained finding but several explanations can be 
posited. AVNRT and AF could share common risk factors but there is little evidence at 
this time that this is the case. Histology of ablated AV nodal tissue shows changes that 
could make it a potential substrate for arrythmia. Qualitatively, RF lesions show more 
pronounced tissue disturbances under microscope and are more ill-defined and 
heterogenous on gross observation when compared with cryo lesions. The question of 
whether these differences impact patient clinical outcomes remains unanswered. Until 
now, no direct comparison between cryoablation and RF examining these issues over 






This multisite retrospective cohort study will compare the rates of AVNRT 
recurrence and newly developed arrythmias between patients who received RF ablation 
and cryoablation. Participants will have undergone ablation between the years of 2005-
2010, representing a 10- to 15-year postprocedural follow-up period. We will utilize a 
records-based approach to determine if a patient has had documented AVNRT recurrence 
or new AF, atrial flutter, or AV nodal block since receiving ablative therapy. In addition, 
participants will complete a short questionnaire regarding their quality of life since the 
ablation procedure. 
 
Study Population and Sampling 
The study population will be all patients who received RF or cryoablation for 
AVNRT at Boston Medical Center, Beth Israel Deaconess Medical Center, and Brigham 
and Women's Hospital between 2005-2010. Inclusion criteria include a diagnosis of 
AVNRT treated with RF or cryoablation between 2005-2010 for AVNRT and an age 
greater than 18. Exclusion criteria include congenital heart disease and other preexisting 
structural heart abnormalities such as hypertrophic cardiomyopathy. We will also exclude 
patients with a documented history of atrial fibrillation, atrial flutter, valvular disease or 
rheumatic heart disease predating ablation. We plan to exclude vulnerable populations 
including prisoners, pregnant women, children, and cognitively impaired persons. 
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In calculating sample size, we used an alpha of 0.05 and a power of 80%. For 
estimation of recurrence risk in the RF group, we used 2.7% based on Frey et al.’s 
findings, which to date describes the longest period follow-up of in patients receiving RF. 
No data is available over a similar timespan for cryoablation but using studies with 
shorter follow-up including Schwagten et al., Rodriguez-Entem et al. and Kimman et al. 
(2004), we will estimate the recurrence risk among the cryoablation group to 12%. Using 
these parameters, we estimate a target sample size of 288 subjects (144 per ablation type). 
 
Exposure Groups 
There will be two groups into which participants will fall. One will be composed 
of patients who received RF ablation for AVNRT between 2005 and 2010, while the 
other will be those who received cryoablation for AVNRT between 2005 and 2010. 
 
Study Variables and Measures 
The primary outcome, recurrence of AVNRT, will be defined as at least one 
documented episode in the patient’s medical record since procedure. Participants need 
not have had repeat ablation to be counted for recurrence. Newly developed arrythmias 
will be defined similarly, as documented episodes of atrial fibrillation or atrial flutter 
since procedure or AV nodal block requiring pacemaker implantation after procedure. 
Finally, a short questionnaire will be utilized to complete demographic 
information and to ask respondents about quality of life change. Participants will be 
asked a single question whether they feel their quality of life has improved, worsened, or 
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had no change as a result of their ablation procedure. Demographic information including 
age, sex, and race will be collected. 
 
Recruitment 
With the help of a cardiologist at each study site, we will compile a list of those 
patients who received either a RF or cryoablation for AVNRT between the years of 2005-
2010. We will reach out by telephone to ask if they are interested in participating in our 
study. Participants will be screened for inclusion and exclusion criteria. Those who 
express interest will be consented to participate in the study and have their medical 
records accessed. For those participants who now receive regular care at other facilities, 
we will get consent to contact and retrieve records from their outside providers. 
Participants will be notified that they will receive a questionnaire in the mail with 
instructions to complete and return. 
 
Data Collection 
Once participants have been consented, trained research assistants will compile 
and review EMR and outside provider records for study-relevant findings, including 
documentation of AVNRT recurrence or new diagnoses of AF, atrial flutter, and AV 
block requiring pacemaker implantation. Research assistants will also record whether 
participants have documented history of conditions associated with cardiac arrythmias 
including hypertension, diabetes, obesity and obstructive sleep apnea. Questionnaires will 
be mailed to participants with prepaid return envelopes enclosed and instructions for 
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completion and return. Research assistants will enter demographic information, study-




Researchers will perform statistical tests to compare the two intervention groups 
(Table 1). To address our primary aim, regarding AVNRT recurrence, we will perform a 
chi-square test to compare recurrence rates between the two groups. The same will be 
done to compare rates of new-onset arrythmias in total and individually for AF, atrial 
flutter, and AV block requiring pacemaker.   
 To rule out demographics as potential sources of confounding, we will also 
analyze demographic information between the two groups. Chi-square tests will be 
performed for categorical variables and a t-test will be performed for continuous 
variables. A further stratified analysis will be used to assess for differences in our 
outcome measures among the different sexes, age groups, and ethnicities.  
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Table 1: Demographics 
Variable Group 1 (RF) Group 2 (Cryo) Comparison 
between groups: 
Statistical Test 
Age Mean +/- SD Mean +/- SD T-test 
Male Sex n (%) n (%) Chi-square 
Ethnicity    
    White n (%) n (%) Chi-square 
    Black n (%) n (%) Chi-square 
   Asian/Pacific 
Islander 
n (%) n (%) Chi-square 
   American Indian n (%) n (%) Chi-square 
   Other n (%) n (%) Chi-square 
Time since 
procedure (years) 
Mean +/- SD Mean +/- SD T-test 
 
Table 2: Outcome Data 
Variable Group 1 (RF) Group 2 (Cryo) Comparison 
between groups: 
Statistical Test 
AVNRT Recurrence n (%) n (%) Chi-square 
New arrythmia n (%) n (%) Chi-square 
    Atrial fibrillation  n (%) n (%) Chi-square 
    Atrial flutter n (%) n (%) Chi-square 
    AV Block n (%) n (%) Chi-square 
Time to recurrence 
(years) 
Mean +/- SD Mean +/- SD T-test 
Quality of Life 
Change 
n (%) n (%) Chi-square 
   Better n (%) n (%) Chi-square 
   Worse n (%) n (%) Chi-square 
   No Change n (%) n (%) Chi-square 
 
Timeline and Resources 
We expect IRB approval across the three participating institutions to take 
approximately 3 months. We estimate recruitment, which will consist of reaching out via 
telephone to a known study population, will take 3 months. Data collection from medical 
records can begin concomitantly with recruiting, once consent has been obtained. 
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Collection of questionnaire data will depend upon the speed of their completion and 
return, which will vary from respondent to respondent. We anticipate data collection as a 
whole will take 4 months. Once data has been collected, data analysis will take 
approximately 2 months. Final preparations and submission for publication will take an 
additional 2 months for a projected total timeline of 14 months. 
Physical resources required will simply be office space with computers with EMR 
capabilities, shipping supplies, and a secure storage place for physical study-related 
documentation and questionnaire responses. Personnel requirements will be 3 
contributing cardiology practitioners, their support staffs, 2 full-time research assistants 
and a statistician. 
 
Institutional Review Board 
As designed, this study poses minimal risk to participants. However, there is a 
risk of privacy breach with the handling and analysis of patient medical records. 
According to BUMC IRB guidelines, collection of survey/questionnaire data from adult 
subjects would fall under Exempt Category 2. Data collected from chart reviews would 
fall under Exempt Category 9, which includes data, documents, and records, that have 
been collected for non-research purposes such as medical treatment or diagnosis. As 
such, a submission will be made to the IRB at Boston University Medical Campus, Beth 
Israel Deaconess Medical Center, and Brigham and Women’s Hospital for “Exempt” 
status. All subjects will be given informed consent for participation in the study and will 






A records-based approach was chosen in part to make barriers of recruitment, 
participation and compliance as low as possible for study subjects. Alternative study 
designs with more active monitoring for recurrence and new arrythmias were considered. 
Bringing subjects in for a physical exam, EKG, or even more invasive testing, such as an 
EP study, would introduce greater burden on subjects and an increase in required 
resources and personnel hours.  
Remote cardiac monitoring program with a Holter monitor or a self-detection 
device such as a Kardia monitor was also considered to confirm recurrence or arrythmia 
on EKG or to detect new ones. This too would greatly increase required material 
resources for the monitors themselves and researcher manpower to analyze the tracings. 
Remote monitoring also introduces issues of subject compliance and proper use. In 
addition, the episodic nature of these arrythmias (excluding complete AV block) does not 
guarantee an event will be detected, even in a compliant subject that does have recurrence 
or new arrythmia. A patient may have infrequent asymptomatic runs of these arrythmias 
but may go through a fourteen-day observation period without an episode. Overall, we 
felt these methods of more intense monitoring were not justified by the limited yield of 
additional information that they would offer in the context of our aims. 
Retrospective cohort studies like this afford certain benefits. Along with being 
less costly, lengthy and labor intensive, retrospective cohort studies are not prone to loss 
to follow up the same way prospective studies are. However, we must also address the 
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limitations of our study design. As a retrospective cohort study with lengthy follow-up 
period, there is the potential that patients in the study population have passed away, 
changed contact information, or are otherwise unreachable. The nature of the disease and 
treatment adds to the issue of differential loss to follow-up. Because ablation is a one-
time definitive treatment for AVNRT, many who are treated with ablation do not require 
subsequent long-term follow-up with cardiology. Maintaining or reestablishing contact 
with such patients may prove more challenging than a patient who has been followed by 
a provider for a chronic condition. This may result in a greater number of patients who 
have no recurring issues being lost to follow-up, which would result in overestimation of 
the rate of recurrence in subjects completing the study.  
This retrospective cohort study carries a risk of selection bias regarding which 
patient received which modality of ablation. Since subjects were not randomized to the 
RF or cryoablation group, other factors could have been involved in the decision of 
which form the patient would receive. A given operator may favor one modality in 
patients with more severe disease, of a certain age group, or with certain history.  
Differences in outcomes between operators is another potential source of 
confounding. Variation in acute success rate and recurrence rate reported across previous 
studies lends credence to the existence of difference in expertise levels between 
operators, or at least differences in operative protocols or standards between facilities. As 
discussed in the Review of Literature, cryoablation has several safety mechanisms, such 
as cryoadhesion and cryomapping, that make it more forgiving and seemingly more 
attractive to a new or less experienced operator. Conversely, RF has been used in practice 
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significantly longer and may be the modality of choice for longer tenured 
electrophysiologists. This difference may prove more significant when considering the 
timeframe in which the study subjects had their ablations performed. With cryoablation 
being popularized in the early 2000’s, operators for our patients had at most 5 to 10 years 
of experience with the cryoablation, while others may have decades of experience with 
RF. To better account for differences in operator experience, analysis that stratified 
operators by procedure volume could be utilized to compare outcomes between high and 
low volume operators utilizing RF vs cryoblation. It should, however, be noted that there 
is no evidence at this time of a difference in competency between operators utilizing 
predominantly RF or cryoablation. 
We defined our variables as at least one documented episode of recurrence or 
arrythmia in a patient’s medical record. We did this in part to mitigate potential recall 
bias likely to emerge if questionnaires and self-reported data were used as the primary 
tool to record recurrence or new arrythmias. Instead, we relied upon the questionnaire 
only for demographic data and subjective feelings on quality of life change. We 
acknowledge the limitations of defining recurrence and new arrythmias in this way. By 
only including documented events found in a patient’s medical record, we will only 
capture clinically relevant episodes, or episodes caught incidentally during healthcare 
visit. However, this fails to detect asymptomatic episodes or subclinical episodes that did 
not drive the patient to seek out care. This will have the effect of underreporting the 
incidence of recurrence and arrythmias in both study arms. This represents a reporting 
 
33 
bias and a potential differential misclassification if disproportionately more 
asymptomatic and subclinical events occurred in one group than the other. 
Arterial hypertension, diabetes, obesity, and obstructive sleep apnea are among 
the many chronic conditions associated with a greater risk of developing AF.  Whether to 
exclude subjects with such conditions predating ablation was also a consideration. They 
also happen to be many of the most common medical conditions in the United States, so 
common that excluding them radically changes the study population and raises concerns 
of generalizability to the US population as a whole. Such exclusion criteria would also 
have a marked effect on recruitment totals. Ultimately, the choice was made to keep these 
patients included in the study. Since researchers will have access to medical records and 
will be aware of such conditions, there remains the possibility of conducting post hoc 
analysis that accounts for these factors. 
It should be noted that, since patients received ablation 10 to 15 years ago, their 
experiences and outcomes may not reflect advancements in technique and practice since 
that time. While this may not greatly affect the long-established RF, this may be more 
significant for cryoablation, which did not reach mainstream use until the early 2000’s. 
 
Summary 
Ablative therapy is first-line definitive treatment for AVNRT. Two modalities, RF 
and cryoablation are highly effective, safe, and widely used. Despite their successes, 
recurrences of AVNRT occur in patients receiving both modalities of ablation. While 
previous groups such as Kimman et al. have argued that recurrence later than 3 years 
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post-surgery was unlikely to happen, Frey et al. observed AVNRT recurrence as late as 
10 years after RF ablation.14,15 Short-term studies suggest cryoablation has a greater 
propensity towards recurrence than RF.13,19,20 Yet no long-term studies of cryoablation 
outcomes are available until now. 
While no causal link has been established between AVNRT ablation and 
development of other arrhythmias, Frey et al.’s findings suggest AF incidence is higher in 
those who receive RF ablation for AVNRT when compared with the general population 
statistics from the CDC and Rotterdam study.14,38,39 This poses interesting questions 
regarding ablative therapy’s impacts on the heart’s electrical conduction system that 




Neither RF nor cryoablation can currently claim superiority as treatment for 
AVNRT. In certain clinical spheres, one may be utilized preferentially, such as the case 
for cryoablation in the pediatric population. However, there is no definitive consensus for 
one modality’s use, either in specific patient groups or the general population. Choice 
between the two is often based on operator preference or availability within the medical 
institution.  
AVNRT adversely affects quality of life. If there exists a difference in the 
effectiveness of RF and cryoablation at permanently treating this condition, then this 
study has the potential to provide a more informed choice of which option will provide 
greater chance of a life without recurrence of AVNRT. By further investigating the long-
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term outcomes of patients who undergo these procedures, our hope is to better equip 
providers and patients with the full risk and benefit profiles of each procedure and guide 
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